Abstract
Hirsh and Poller 1 have examined a number of potential problems that may affect the reliability of the prothrombin time ratio and the international normalized ratio by highlighting sources of variability in the prothrombin time ratio and explaining how some of these are lessened by using the international normalized ratio. However, their article does not adequately emphasize the clinical impact that these inaccuracies have on patient care. The major concern in monitoring the intensity of anticoagulation therapy is how variability in either the prothrombin time ratio or the international normalized ratio affect the likelihood of adverse outcomes, bleeding and thromboemboli. Clinicians must separate variation in their patients' level of anticoagulation from variability introduced in the laboratory. By not accounting for variability in the sensitivity of thromboplastins to the depletion of the vitamin K—dependent coagulation factors, the prothrombin time ratio alone introduces needless uncertainty in the true level of anticoagulation intensity.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
